Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma

HepatologyVolume 74, Issue 1 p. 483-490 Concise Review Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma David J. Pinato, Corresponding Author David J. Pinato david.pinato@imperial.ac.uk Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, United KingdomThese are joint first authors. ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO: David J. Pinato, M.D., M.Res., M.R.C.P., Ph.D. Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Du Cane Road W12 0HS, London, UK E-mail: david.pinato@imperial.ac.uk Tel.: +44 020 83833720Search for more papers by this authorPetros Fessas, Petros Fessas Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, United KingdomThese are joint first authors.Search for more papers by this authorGonzalo Sapisochin, Gonzalo Sapisochin Multi-Organ Transplant and HPB Surgical Oncology, Division of General Surgery, Toronto General Hospital, Department of Surgery, University of Toronto, Toronto, CanadaThese are joint senior authors.Search for more papers by this authorThomas U. Marron, Thomas U. Marron Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NYThese are joint senior authors.Search for more papers by this author David J. Pinato, Corresponding Author David J. Pinato david.pinato@imperial.ac.uk Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, United KingdomThese are joint first authors. ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO: David J. Pinato, M.D., M.Res., M.R.C.P., Ph.D. Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Du Cane Road W12 0HS, London, UK E-mail: david.pinato@imperial.ac.uk Tel.: +44 020 83833720Search for more papers by this authorPetros Fessas, Petros Fessas Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, United KingdomThese are joint first authors.Search for more papers by this authorGonzalo Sapisochin, Gonzalo Sapisochin Multi-Organ Transplant and HPB Surgical Oncology, Division of General Surgery, Toronto General Hospital, Department of Surgery, University of Toronto, Toronto, CanadaThese are joint senior authors.Search for more papers by this authorThomas U. Marron, Thomas U. Marron Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NYThese are joint senior authors.Search for more papers by this author First published: 28 December 2020 https://doi.org/10.1002/hep.31697Citations: 6 Supported by grant funding from the Wellcome Trust Strategic Fund (PS3416, to D.J.P.). Potential conflict of interest: Dr. Marron advises and received grants from Regeneron. He advises AstraZeneca and Genentech. He received grants from Bristol-Myers Squibb. Dr. Pinato consults and is on the speakers’ bureau for Roche. He consults for Mina and Eisai. He advises AstraZeneca. He is on the speakers’ bureau for Bayer and Viiv. He received grants from MSD and Bristol-Myers Squibb. Dr. Sapisochin consults for and received grants from Roche. He consults for AstraZeneca and received grants from Bayer. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume74, Issue1July 2021Pages 483-490 RelatedInformation